Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)

China flag China · Delayed Price · Currency is CNY
46.18
+0.55 (1.21%)
Feb 3, 2026, 3:04 PM CST
54.76%
Market Cap50.87B +48.2%
Revenue (ttm)4.25B +8.8%
Net Income672.56M +10.1%
EPS0.60 +9.2%
Shares Out1.11B
PE Ratio76.02
Forward PE75.80
Dividend0.50 (1.07%)
Ex-Dividend DateMay 14, 2025
Volume7,130,513
Average Volume8,001,972
Open47.33
Previous Close45.63
Day's Range44.95 - 47.33
52-Week Range27.66 - 65.63
Beta0.61
RSI26.33
Earnings DateMar 24, 2026

About SHE:002294

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also develops Sacubitril Allisartan Calcium, Allisartan Isoproxil Amlodipine Besylate Tablets, and Allisartan IsoproxilIndapamide Sustained-release Tablets, which are in ph... [Read more]

Sector Healthcare
Founded 1998
Employees 3,596
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002294
Full Company Profile

Financial Performance

In 2024, SHE:002294's revenue was 4.01 billion, an increase of 19.22% compared to the previous year's 3.37 billion. Earnings were 601.57 million, an increase of 3.71%.

Financial Statements